Lenalidomide decreased the PSA level for castration‐resistant prostate cancer: a case report

Publisher: John Wiley & Sons Inc

E-ISSN: 2050-0904|6|2|391-394

ISSN: 2050-0904

Source: Clinical Case Reports, Vol.6, Iss.2, 2018-02, pp. : 391-394

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Key Clinical MessageLenalidomide has been developed as the derivative of thalidomide that has fewer side effects. We herein report a rare case of castration‐resistant prostate cancer successfully maintained using lenalidomide for multiple myeloma.